ScholarLens Back to search
2017•NeurologyRequires access

Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide (P6.372)

Timothy Spelman, Tomáš Kalinčík, Maria Trojana, François Grand’Maison, Guillermo Izquierdo, Eva Havrdová, Dana Horáková, Alessandra Lugaresi, Pierre Duquette, Pierre Grammond, Raymond Hupperts, Jeannette Lechner‐Scott, Franco Granella, Thor Petersen, Murat Terzi, Eugenio Pucci, Patrizia Sola, Vincent Van Pesch, Gerardo Iuliano, Cavit Boz, Roberto Bergamaschi, Mark Slee, Helmut Butzkueven

Open publisher page 4 citations

Abstract

Compare time to first relapse (TTFR), annualized relapse rate (ARR), and discontinuation outcomes in patients initiating dimethyl fumarate (DMF) pair-wise versus a propensity-matched cohort of fingolimod (FTY), teriflunomide (TERI), interferons (IFN), or glatiramer acetate (GA).

About this research paper

What this paper is about

Compare time to first relapse (TTFR), annualized relapse rate (ARR), and discontinuation outcomes in patients initiating dimethyl fumarate (DMF) pair-wise versus a propensity-matched cohort of fingolimod (FTY), teriflunomide (TERI), interferons (IFN), or glatiramer acetate (GA).

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Compare time to first relapse (TTFR), annualized relapse rate (ARR), and discontinuation outcomes in patients initiating dimethyl fumarate (DMF) pair-wise versus a propensity-matched cohort of fingolimod (FTY), teriflunomide (TERI), interferons (IFN), or glatiramer acetate (GA).

Key concepts: Glatiramer acetate, Teriflunomide, Fingolimod, Dimethyl fumarate, Medicine, Multiple sclerosis, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide (P6.372) — Research Paper | ScholarLens